JP2005502357A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502357A5 JP2005502357A5 JP2003527090A JP2003527090A JP2005502357A5 JP 2005502357 A5 JP2005502357 A5 JP 2005502357A5 JP 2003527090 A JP2003527090 A JP 2003527090A JP 2003527090 A JP2003527090 A JP 2003527090A JP 2005502357 A5 JP2005502357 A5 JP 2005502357A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cells
- medium
- culture
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 42
- 241000700605 Viruses Species 0.000 claims 28
- 208000015181 infectious disease Diseases 0.000 claims 10
- 239000002609 medium Substances 0.000 claims 10
- 230000012010 growth Effects 0.000 claims 7
- 238000004113 cell culture Methods 0.000 claims 6
- 239000012141 concentrate Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000001963 growth medium Substances 0.000 claims 4
- 239000012092 media component Substances 0.000 claims 4
- 239000012737 fresh medium Substances 0.000 claims 3
- 238000000746 purification Methods 0.000 claims 3
- 241001529453 unidentified herpesvirus Species 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 241000702263 Reovirus sp. Species 0.000 claims 2
- 238000004115 adherent culture Methods 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004114 suspension culture Methods 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241000712891 Arenavirus Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000701157 Canine mastadenovirus A Species 0.000 claims 1
- 208000037404 Central European encephalitis Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012533 medium component Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 241001147420 ssDNA viruses Species 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 238000005199 ultracentrifugation Methods 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10144903A DE10144903A1 (de) | 2001-09-12 | 2001-09-12 | Vermehrung von Viren in Zellkultur |
| PCT/EP2002/010207 WO2003023025A1 (de) | 2001-09-12 | 2002-09-11 | Vermehrung von viren in zellkultur |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010145663A Division JP2010246559A (ja) | 2001-09-12 | 2010-06-25 | 細胞培養物中のウイルス増殖 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502357A JP2005502357A (ja) | 2005-01-27 |
| JP2005502357A5 true JP2005502357A5 (https=) | 2006-01-05 |
Family
ID=7698761
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003527090A Pending JP2005502357A (ja) | 2001-09-12 | 2002-09-11 | 細胞培養物中のウイルス増殖 |
| JP2010145663A Pending JP2010246559A (ja) | 2001-09-12 | 2010-06-25 | 細胞培養物中のウイルス増殖 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010145663A Pending JP2010246559A (ja) | 2001-09-12 | 2010-06-25 | 細胞培養物中のウイルス増殖 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050118698A1 (https=) |
| EP (1) | EP1427817B1 (https=) |
| JP (2) | JP2005502357A (https=) |
| KR (1) | KR100968141B1 (https=) |
| AT (1) | ATE466932T1 (https=) |
| AU (1) | AU2002338666B2 (https=) |
| BR (1) | BR0212469A (https=) |
| CA (1) | CA2456561A1 (https=) |
| CY (1) | CY1110716T1 (https=) |
| DE (2) | DE10144903A1 (https=) |
| DK (1) | DK1427817T3 (https=) |
| ES (1) | ES2345606T3 (https=) |
| NZ (1) | NZ532203A (https=) |
| PT (1) | PT1427817E (https=) |
| SI (1) | SI1427817T1 (https=) |
| WO (1) | WO2003023025A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007537760A (ja) * | 2004-05-20 | 2007-12-27 | アイディー バイオメディカル コーポレイション | インフルエンザワクチンを製造するためのプロセス |
| ATE489965T1 (de) | 2004-09-09 | 2010-12-15 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
| ES2525518T3 (es) | 2005-11-01 | 2014-12-26 | Novartis Vaccines And Diagnostics Gmbh | Vacunas virales derivadas de células con niveles reducidos de ADN celular residual |
| JP2009514844A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| NZ594482A (en) | 2005-11-04 | 2012-11-30 | Novartis Vaccines & Diagnostic | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant |
| CA2628152C (en) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| CN102755645A (zh) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | 佐剂配制的包含细胞因子诱导剂的流感疫苗 |
| CN101448523A (zh) | 2006-03-24 | 2009-06-03 | 诺华疫苗和诊断有限两合公司 | 无需冷藏储存流感疫苗 |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP4585610A3 (en) * | 2006-09-11 | 2025-09-24 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| EP2615167A1 (en) | 2006-09-15 | 2013-07-17 | MedImmune, LLC | Method for eliminating DNA contaminants from viral preparations |
| KR20100045437A (ko) | 2007-06-27 | 2010-05-03 | 노파르티스 아게 | 첨가물이 적은 인플루엔자 백신 |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| US8785173B2 (en) | 2008-09-24 | 2014-07-22 | Medimmune, Llc | Methods for purification of viruses |
| EP2344634A4 (en) | 2008-09-24 | 2012-08-29 | Medimmune Llc | METHODS OF CELL CULTURE, AND PROPAGATION AND PURIFICATION OF VIRUSES |
| CA2741961A1 (en) | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
| USH2283H1 (en) | 2009-04-27 | 2013-09-03 | Novartis Ag | Vaccines for protecting against influenza |
| CA2778332A1 (en) * | 2009-10-20 | 2011-04-28 | Novartis Ag | Improved reverse genetics methods for virus rescue |
| BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
| US9426989B2 (en) | 2010-05-06 | 2016-08-30 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
| CN103025350A (zh) | 2010-05-21 | 2013-04-03 | 诺华有限公司 | 流感病毒的重配方法 |
| WO2011151723A2 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens without lyophilization |
| CA2801151A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| WO2012023044A1 (en) | 2010-08-20 | 2012-02-23 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
| SG192821A1 (en) * | 2011-02-17 | 2013-09-30 | Boehringer Ingelheim Vetmed | Commercial scale process for production of prrsv |
| CA2829774C (en) | 2011-03-14 | 2019-09-24 | National Research Council Of Canada | Method of viral production in cells |
| GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| EP2822585B1 (en) | 2012-03-06 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Improved vaccination against influenza |
| WO2014031480A1 (en) * | 2012-08-24 | 2014-02-27 | Xcellerex, Inc. | Virus purification and formulation process |
| KR101370512B1 (ko) * | 2013-06-07 | 2014-03-06 | 재단법인 목암생명공학연구소 | 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법 |
| US11013795B2 (en) | 2015-06-26 | 2021-05-25 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| KR102790570B1 (ko) | 2015-07-07 | 2025-04-04 | 세퀴러스 유케이 리미티드 | 인플루엔자 효능 검정 |
| CN105561317B (zh) * | 2015-12-22 | 2018-03-20 | 肇庆大华农生物药品有限公司 | 重组伪狂犬病病毒疫苗耐热冻干保护剂及其制备方法 |
| CN108239619A (zh) * | 2016-12-23 | 2018-07-03 | 甘肃健顺生物科技有限公司 | 悬浮mdck细胞相关疫苗生产的二阶培养工艺技术 |
| CN108570444A (zh) * | 2017-11-09 | 2018-09-25 | 甘肃健顺生物科技有限公司 | St细胞驯化悬浮方法和二阶病毒生产工艺 |
| CN108570445A (zh) * | 2017-11-09 | 2018-09-25 | 甘肃健顺生物科技有限公司 | Pk15细胞驯化悬浮方法和二阶病毒生产工艺 |
| CN108570454A (zh) * | 2017-11-09 | 2018-09-25 | 甘肃健顺生物科技有限公司 | Mdbk驯化悬浮方法和二阶病毒生产工艺 |
| EP4061930A1 (en) | 2019-11-18 | 2022-09-28 | Seqirus Pty Ltd | Method for producing reassortant influenza viruses |
| KR102444684B1 (ko) * | 2020-04-29 | 2022-09-16 | 에스케이바이오사이언스(주) | 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| KR19990072201A (ko) * | 1996-10-18 | 1999-09-27 | 무타이 마사히꼬 | 로타바이러스 항원, 로타바이러스 감염증에 대한백신 및 진단제와 항원 제조방법 |
| GB9915413D0 (en) * | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Propagation method |
| KR100797547B1 (ko) * | 2000-03-03 | 2008-01-24 | 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
-
2001
- 2001-09-12 DE DE10144903A patent/DE10144903A1/de not_active Ceased
-
2002
- 2002-09-11 JP JP2003527090A patent/JP2005502357A/ja active Pending
- 2002-09-11 CA CA002456561A patent/CA2456561A1/en not_active Abandoned
- 2002-09-11 WO PCT/EP2002/010207 patent/WO2003023025A1/de not_active Ceased
- 2002-09-11 ES ES02777068T patent/ES2345606T3/es not_active Expired - Lifetime
- 2002-09-11 KR KR1020047003711A patent/KR100968141B1/ko not_active Expired - Lifetime
- 2002-09-11 AT AT02777068T patent/ATE466932T1/de active
- 2002-09-11 EP EP02777068A patent/EP1427817B1/de not_active Expired - Lifetime
- 2002-09-11 DE DE50214416T patent/DE50214416D1/de not_active Expired - Lifetime
- 2002-09-11 AU AU2002338666A patent/AU2002338666B2/en not_active Ceased
- 2002-09-11 PT PT02777068T patent/PT1427817E/pt unknown
- 2002-09-11 DK DK02777068.4T patent/DK1427817T3/da active
- 2002-09-11 NZ NZ532203A patent/NZ532203A/en not_active IP Right Cessation
- 2002-09-11 US US10/487,709 patent/US20050118698A1/en not_active Abandoned
- 2002-09-11 SI SI200230909T patent/SI1427817T1/sl unknown
- 2002-09-11 BR BR0212469-6A patent/BR0212469A/pt not_active IP Right Cessation
-
2010
- 2010-06-25 JP JP2010145663A patent/JP2010246559A/ja active Pending
- 2010-07-30 CY CY20101100718T patent/CY1110716T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502357A5 (https=) | ||
| JP2005532779A5 (https=) | ||
| CA2455189A1 (en) | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture | |
| ES2335395T3 (es) | Metodo mejorado para la produccion a escala de antigenos virales. | |
| JP2009034115A5 (https=) | ||
| JP2010138205A5 (https=) | ||
| KR20030032923A (ko) | 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 | |
| JP2005502357A (ja) | 細胞培養物中のウイルス増殖 | |
| JP2013515473A5 (https=) | ||
| TW201311896A (zh) | 製備病毒抗原及疫苗之方法 | |
| AU2015294014A1 (en) | Process for the purification of poliovirus from cell cultures | |
| IL190578A (en) | A viro cell line and a method to create a virus to prepare vaccines from it | |
| JP2021528999A (ja) | エンベロープウイルスの精製方法 | |
| CN1617923A (zh) | 大规模生产甲型肝炎病毒的方法 | |
| CN110268052A (zh) | 纯化病毒的方法 | |
| EP2155863B1 (en) | Two-step temperature profile for the propagation of viruses | |
| WO2026030180A1 (en) | A method for optimizing vero cell growth | |
| HK1115609B (en) | Method for large scale production of virus antigen | |
| CN1470641A (zh) | 一种用于筛选和评价抗hcv药物的方法及其应用 | |
| HK1158691B (en) | Method for large scale production of virus | |
| HK1137780B (en) | Two-step temperature profile for the propagation of viruses |